Amgen Inc.'s bid to get approved an I.V. replacement for its oral Sensipar hit choppy seas in the form of a complete response letter from the FDA on its PDUFA date regarding the NDA for Parsabiv (etelcalcetide), designed to treat secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis.